ContraFect to Present New Data on CF-301 at ID Week 2017

YONKERS, N.Y., Sept. 29, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces poster presentations of new data from the CF-301 development program at the ID Week 2017 conference to be held on October 4-8, 2017 in San Diego, CA.

“We are pleased to present new data which further support the intended use of CF-301 for the treatment of Staphylococcus aureus (Staph aureus) infections.  These new data extend previous reports of CF-301’s synergy with conventional antibiotics to a wider range of commonly used anti-staphylococcal antibiotics and suggest that CF-301 may enhance the ability of antibiotics to treat serious infections. We are further encouraged by the additional surveillance data which show the potent activity of CF-301 against current Staph aureus strains from infected patients in diverse geographies,” said Cara Cassino, M.D., EVP of Research and Development and Chief Medical Officer at ContraFect.

Presentation Details:

Session Title: Expanded Spectrum - New Antimicrobial Susceptibility Testing

Presentation Title: Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus
Session Day & Time: Friday, October 6, 2017 12:30 PM – 2:00 PM PT (3:30 PM – 5:00 PM ET)
Poster Number: 1212

Presentation Title: Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA and Europe
Session Day & Time: Friday, October 6, 2017 12:30 PM – 2:00 PM PT (3:30 PM – 5:00 PM ET)
Poster number: 1213

The abstracts can be accessed through the ID Week website. Following the meeting, the presentation posters will be available on the ContraFect Corporation website.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza. ContraFect is also conducting research focused on the discovery of lysins to target Gram-negative bacteria.

About CF-301:

CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia.  It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect. CF-301 is currently being studied in a Phase 2 multicenter, multinational, randomized, controlled clinical trial in patients with Staph aureus bacteremia including endocarditis.

Forward-Looking Statements

This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws.  Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, whether new data on CF-301 supports its intended use, our ability to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses, whether our initial product candidates can treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza, our ability to discover new lysins targeting Gram-negative bacteria and the potential for CF-301 to be a first-in-class treatment for Staph aureus bacteremia. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect's filings with the Securities and Exchange Commission.  Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact

Paul Boni 
ContraFect Corporation 
Tel: 914-207-2300
Email: pboni@contrafect.com

Primary Logo

Source: ContraFect Corporation